$ALT

Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares

Deep Track Capital, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and Deep Track Special Opportunities Fund, LP, and David Kroin, has reported a 9.99% beneficial ownership stake in Altimmune (ALT). This stake, amounting to 19,417,221 shares, includes common stock, pre-funded warrants, and warrants, all subject to a 9.99% maximum exercise limitation. The disclosure was made via a Schedule 13G filing as of April 30, 2026 and is based on 194,366,579 shares outstanding.

Original reporting
Published May 1, 2026, 6:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 6:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ALT
Neutral
medium confidence
Mentioned
$ALT
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$ALTNeutralLow
01

Why it matters

While the disclosure indicates institutional interest, it does not necessarily translate into active trading signals or immediate price movements.

02

Market read

The disclosure is relevant for investors monitoring institutional holdings and potential market sentiment shifts in ALT.

03

What to watch

Broader market conditions, company fundamentals, and upcoming catalysts are critical to assess before making trading decisions.

Timing: short-term (within days to weeks)

Background

Institutional investors are required to disclose holdings exceeding 5% in US-listed companies, providing transparency about significant passive interests.

Company-level read

Ticker impact

$ALTNeutralMedium confidence
Context

The disclosed 9.99% passive stake in Altimmune (ALT) indicates significant institutional interest, which can influence market perception and stock price movements.

Expected impact

Potential for moderate upward price movement if market interprets increased institutional interest as positive; however, the passive nature limits immediate impact.

Evidence & confidence

The passive stake indicates interest but lacks active trading signals; market reaction depends on broader context and investor perception.

Market effects

Possible increased investor focus on biotech and life sciences sectors due to institutional activity in ALT.

Limited regional impact; primarily relevant to US markets where ALT is listed.

Minimal; the news pertains to a specific US-listed company with no immediate global implications.

Counterpoint

Passive stake may not lead to significant price change; market may have already priced in institutional interest.

Key entities

  • Deep Track Capital

    A hedge fund or investment firm reporting a 9.99% stake in ALT.

  • Altimmune (ALT)

    A biotech company in the life sciences sector.

Related articles

$ALTMedAI 8/10

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial

Altimmune (NASDAQ:ALT) reported Phase II results for pemvidutide in alcohol use disorder. The WHO risk-drinking-level endpoint improved in 64.4% vs 34.8% on placebo (p=0.0049), and zero heavy drinking days increased with p=0.0066. PEth fell by 175.3 ng/mL vs unchanged on placebo (p=0.0001). Safety was generally tolerable; Phase III AUD discussions with regulators are next.

$ALTMedAI 8/10

Why is Altimmune stock surging today? By Investing.com

Altimmune said its RECLAIM Phase 2 trial of pemvidutide for moderate to severe alcohol use disorder met the primary endpoint, with 2.4 mg producing a statistically significant reduction in heavy drinking days per week versus placebo over 24 weeks (treatment effect 1.45 days). It also met secondary endpoints, and the company plans an End-of-Phase 2 meeting with the FDA. Shares rose 11.5% pre-open.

$ALTMedAI 8/10

Altimmune stock surges 18% on positive trial results By Investing.com

Altimmune Inc. (NASDAQ:ALT) shares rose 18% after it reported positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The study met its primary endpoint with a statistically significant reduction in heavy drinking days versus placebo (4.20 vs 2.75 per week at week 24, p=0.0014). Secondary endpoints and safety data were also favorable, and the company plans an FDA End-of-Phase 2 meeting.

$MDTMed

Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.